Selected article for: "PCR assay and reaction condition"
Author: Xu, Gang; Liu, Feng; Ye, Min; Zhao, Jun; Li, Qing; Feng, Congrui; Hu, Yudong; Li, Yueping; Shi, Haiyan; Zhang, Fuchun; Tong, Yuwei; Ma, Wei
Title: No Evidence of Re-infection or Person-to-Person Transmission in Cured COVID-19 Patients in Guangzhou, a Retrospective Observational Study
  • Cord-id: pmufpksg
  • Document date: 2020_11_30
    • ID: pmufpksg
    Snippet: Objectives: To clarify the clinical characteristics of cured patients with coronavirus disease (COVID-19), and to clarify the re-infection and person-to-person transmission in the cured. Methods: A total of 187 cured COVID-19 patients with antibody test were followed up every 2 weeks in this retrospective observational study. Assessment for general condition, symptoms, epidemiological contact history, polymerase chain reaction (PCR) assay, and antibody tests were performed and recorded. Informat
    Document: Objectives: To clarify the clinical characteristics of cured patients with coronavirus disease (COVID-19), and to clarify the re-infection and person-to-person transmission in the cured. Methods: A total of 187 cured COVID-19 patients with antibody test were followed up every 2 weeks in this retrospective observational study. Assessment for general condition, symptoms, epidemiological contact history, polymerase chain reaction (PCR) assay, and antibody tests were performed and recorded. Information from Guangzhou CDC was also screened. Results: There were 33 (17.6%) patients with negative results for IgG and 35 (18.7%) patients with positive results for IgM. The average days of antibody detection from disease onset were 53.0. PCR assay was positive in 10 (5.3%) patients during the follow-up. Neither IgG nor IgM results showed a relationship with PCR test results (all P > 0.05). Neither re-infection nor person-to-person transmission was found in the cured patients. Factors associated with appearance of antibody comprised hospitalization days (OR: 1.06, 95%CI: 1.02–1.11, P = 0.006) and antibiotics treatment (OR: 3.50, 95%CI: 1.40–8.77, P = 0.007). Conclusions: In our study, no evidence of person-to-person transmission was found in cured COVID-19 patients. There seemed to be no re-infection in the cured COVID-19 patients in Guangzhou. These finding suggest that the cured do not cause the spread of disease. Additionally, neither IgG nor IgM can be used to replace the PCR test in cured patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • abnormal chest and additional patient: 1
    • abnormal chest and liver failure: 1
    • abnormal chest and living area: 1
    • abnormal chest ct and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • abnormal chest ct and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal chest ct and additional patient: 1
    • active remain and acute infection: 1
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and additional patient: 1, 2
    • acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute heart injury and liver failure: 1, 2
    • acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and additional patient: 1, 2, 3
    • acute infection and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and living area: 1, 2, 3, 4, 5
    • acute infection patient and liver failure: 1, 2, 3
    • acute liver failure and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute liver failure septic shock and liver failure: 1, 2, 3